RC28-E

BIOLOGICAL2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Neovascular Age-related Macular DegenerationWet Age-related Macular Degeneration

Phase 1

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

CompletedNCT03777254

RemeGen Co., Ltd.Neovascular Age-related Macular Degeneration

Start: 2019-01-07End: 2019-08-20Updated: 2021-04-27

Phase 3

Efficacy and Safety of RC28-E Versus Aflibercept

RemeGen Co., Ltd.Wet Age-related Macular Degeneration

Start: 2023-03-14End: 2025-12-29Target: 432Updated: 2023-08-31

Related Papers

Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model

Biomolecules2019-10-245 citations